Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study

Mod Rheumatol. 2021 Jan;31(1):162-170. doi: 10.1080/14397595.2020.1751408. Epub 2020 Apr 21.

Abstract

Objectives: To investigate the clinical course of Japanese patients with early diffuse cutaneous systemic sclerosis (dcSSc) and early SSc with interstitial lung disease (ILD).

Methods: We prospectively analyzed the clinical features of 207 Japanese patients with early dcSSc (n = 150) and limited cutaneous SSc (lcSSc) with ILD (n = 57) in 10 medical centers every year for 7 consecutive years.

Results: Mean modified Rodnan total skin thickness score (mRSS) was 18.3 and 67.4% of the cohort had ILD. Most patients started immunosuppressive therapy and vasodilators during 7 years (83.4% and 87.9%, respectively). Mean value of mRSS of total patients was significantly reduced from the initial registration after the first year. However, other parameters for physical function associated with skin sclerosis including fist closure, hand extension, and oral aperture were not so ameliorated during the study period. Health Assessment Questionnaire-disability index and serum KL-6 levels were constant throughout the course. Percent vital capacity and the presence of ILD, clinically suspected pulmonary arterial hypertension, and digital ulcers were gradually exacerbated during the period.

Conclusion: In Japanese early dcSSc patients and SSc patients with ILD, mRSS was continuously reduced during 7 years of follow-up, but there was little improvement of physical disability and organ involvement.

Keywords: Clinical course; interstitial lung disease; skin sclerosis; systemic sclerosis; treatment outcome.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Adult
  • Female
  • Hand / physiopathology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Japan
  • Lung Diseases, Interstitial / epidemiology*
  • Male
  • Middle Aged
  • Pressure Ulcer / epidemiology*
  • Scleroderma, Diffuse / complications
  • Scleroderma, Diffuse / drug therapy
  • Scleroderma, Diffuse / pathology*
  • Skin / pathology
  • Vital Capacity

Substances

  • Immunosuppressive Agents